Search: onr:"swepub:oai:gup.ub.gu.se/52252" >
Effect of candesart...
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program
-
Solomon, S. D. (author)
-
Wang, D. (author)
-
Finn, P. (author)
-
show more...
-
Skali, H. (author)
-
Zornoff, L. (author)
-
McMurray, J. J. (author)
-
- Swedberg, Karl, 1944 (author)
- Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute
-
Yusuf, S. (author)
-
Granger, C. B. (author)
-
Michelson, E. L. (author)
-
Pocock, S. (author)
-
Pfeffer, M. A. (author)
-
show less...
-
(creator_code:org_t)
- 2004
- 2004
- English.
-
In: Circulation. - 1524-4539. ; 110:15, s. 2180-3
- Related links:
-
https://gup.ub.gu.se...
Abstract
Subject headings
Close
- BACKGROUND: Patients with heart failure are at increased risk of sudden death and death attributed to progressive pump failure. We assessed the effect of candesartan on cause-specific mortality in patients enrolled in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. METHODS AND RESULTS: The CHARM program consisted of 3 component trials that enrolled patients with symptomatic heart failure: CHARM-Alternative (n=2028; LVEF<=40% [corrected] and ACE intolerant), CHARM-Added (n=2548; LVEF<=40%, [corrected] already on ACE inhibitors), and CHARM-Preserved (n=3023; LVEF >40%). Patients were randomized to candesartan, titrated to 32 mg QD, or placebo and were followed up for a median of 37.7 months. All deaths were reviewed by a blinded adjudication committee and categorized according to prespecified definitions on the basis of a narrative and source documentation. The number and rate of deaths by cause were calculated for each of the component trials and the overall program. Of all the patients, 8.5% died suddenly, and 6.2% died of progressive heart failure. Candesartan reduced both sudden death (HR 0.85 [0.73 to 0.99], P=0.036) and death from worsening heart failure (HR 0.78 [0.65 to 0.94], P=0.008). These reductions were most apparent in the patients with LVEF<=40% [corrected]. CONCLUSIONS: Candesartan reduced sudden death and death from worsening heart failure in patients with symptomatic heart failure, although this reduction was most apparent in patients with systolic dysfunction.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Keyword
- Aged
- Angiotensin II Type 1 Receptor Blockers/*therapeutic use
- Benzimidazoles/*therapeutic use
- Canada/epidemiology
- Cardiovascular Diseases/*mortality/prevention & control
- Cause of Death
- Death
- Sudden
- Cardiac/epidemiology/prevention & control
- Disease Progression
- Female
- Great Britain/epidemiology
- Heart Failure
- Congestive/*drug therapy/mortality
- Humans
- Male
- Middle Aged
- Proportional Hazards Models
- Single-Blind Method
- Sweden/epidemiology
- Tetrazoles/*therapeutic use
- United States/epidemiology
- Ventricular Dysfunction
- Left/mortality/prevention & control
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Solomon, S. D.
-
Wang, D.
-
Finn, P.
-
Skali, H.
-
Zornoff, L.
-
McMurray, J. J.
-
show more...
-
Swedberg, Karl, ...
-
Yusuf, S.
-
Granger, C. B.
-
Michelson, E. L.
-
Pocock, S.
-
Pfeffer, M. A.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
Circulation
- By the university
-
University of Gothenburg